Skip to main content

Xortx Therapeutics Inc(XRTX-X)
TSX Venture

Today's Change
Delayed Last Update
Day Low0.600
Day High0.600
Open:0.600
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change

TOP STORIES: Xortx Therapeutics Inc

Select a category then submit the form to load news
GlobeNewswire
XORTX Announces Filing and Mailing of the Meeting Documents in Connection with the Annual and Special Meeting of Shareholders
Newsfile
Upcoming Meeting Dates - February 9, 2026
GlobeNewswire
XORTX Provides Update on Acquisition of Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems
GlobeNewswire
XORTX Announces Pioneering Research on Genome-Wide Pathogenic Pathways in Gout and Provides a Corporate Update
Newsfile
Upcoming Meeting Dates - December 22, 2025
GlobeNewswire
XORTX Announces Pricing of US$1.1 Million Registered Direct Offering
GlobeNewswire
XORTX Issues Correction Notice and XORTX Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Deficiency
GlobeNewswire
XORTX Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
GlobeNewswire
XORTX Announces Acquisition of Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems
GlobeNewswire
Join XORTX for an Exclusive Live Investor Webinar and Q&A Session on September 10
GlobeNewswire
XORTX Initiates IND Preparation for XORLO™ in Gout Program
GlobeNewswire
XORTX Completes USD $114,500 Private Placement
GlobeNewswire
XORTX Announces USD $114,500 Private Placement
GlobeNewswire
XORTX Completes Non-Brokered Private Placement of Units
GlobeNewswire
XORTX Announces USD $925,000 Private Placement
AI-generated - The Globe and Mail
XORTX Therapeutics: Stocks Undervalued by Analyst Consensus on TSX-V (XRTX)
GlobeNewswire
XORTX Announces USD $3 Million Offering
AI-generated - The Globe and Mail
XORTX Therapeutics: Top 10 Undervalued Biotechnology Industry Stocks (XRTX)
AI-generated - The Globe and Mail
XORTX Therapeutics: Stocks Undervalued by Analyst Consensus on TSX-V (XRTX)
GlobeNewswire
XORTX Provides Update on FDA Type B Meeting Request
AI-generated - The Globe and Mail
XORTX Therapeutics: Top 10 Undervalued Biotechnology Industry Stocks (XRTX)
AI-generated - The Globe and Mail
XORTX Therapeutics: Stocks Undervalued by Analyst Consensus on TSX-V (XRTX)
AI-generated - The Globe and Mail
XORTX Therapeutics: Top 10 Undervalued Biotechnology Industry Stocks (XRTX)
GlobeNewswire
XORTX Announces Update for Discussion with the FDA
GlobeNewswire
XORTX Commences Gout Program NDA Discussions with the FDA
GlobeNewswire
XORTX to Present at Microcap Conference
AI-generated - The Globe and Mail
XORTX Therapeutics: Top 10 Undervalued Biotechnology Industry Stocks (XRTX)
GlobeNewswire
XORTX Announces Change of Auditor
GlobeNewswire
XORTX Adds Late Stage Gout Program to Pipeline
AI-generated - The Globe and Mail
XORTX Therapeutics: Top 10 Undervalued Biotechnology Industry Stocks (XRTX)
GlobeNewswire
XORTX Strengthens Executive Team
GlobeNewswire
XORTX Announces Presentation at the Rare and Genetic Disease Summit

Profile

XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.